CytomX Therapeutics CTMX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total External Costs by Product | ||||||
| Cx801Ifnalpha2B | $1.48M-8.8% | $1.63M-7.2% | $1.75M-4.7% | $1.84M-7.7% | $1.99M-20.4% | |
| Other Wholly Owned And Partnered Programs | $1.67M-13.2% | $1.92M-32.2% | $2.84M-10.2% | $3.16M-26.3% | $4.29M-39.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does CytomX Therapeutics break its business down?
- CytomX Therapeutics (CTMX) reports total external costs by product across 5 parts — Cx801Ifnalpha2B, Cx904Egfrxcd3, Other Wholly Owned And Partnered Programs, Varseta-M Ep CAM and Varseta-M. Each is extracted from the segment footnotes and tracked over time.
- Where does CytomX Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in CytomX Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
